Bullish
Genmab and AbbVie's Phase 3 EPCORE DLBCL-4 trial for epcoritamab in relapsed or refractory DLBCL met its primary goal, showing significant improvement...
A bipartisan group of U.S. lawmakers is investigating five major pharmaceutical companies, including Merck and AbbVie, regarding their clinical trials...
AbbVie Inc. (ABBV) is set to trade ex-dividend on July 15, positioning it as a top dividend stock for July. The company recently received FDA approval...
AbbVie announced positive topline Phase 3 results for epcoritamab combined with lenalidomide in patients with relapsed or refractory diffuse large B-c...
Bullish
This article analyzes AbbVie's stock performance following a 41% rally over the past year, evaluating its current valuation. Using a Discounted Cash F...
AbbVie stock recently hit a new 52-week high, but despite its 40% gain over the past year, it has only risen 11% year-to-date, suggesting it hasn't be...
Bullish
AbbVie's stock has surged, gaining approximately $65 billion in market value since June 18, which is about six times the $10.9 billion cash it's payin...
Bullish
AbbVie Inc. (NYSE:ABBV) announced its definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion. This acquisition, approved ...
Neutral
AbbVie Inc (ABBV) shares rose 4.2% to $253.35, but GuruFocus' GF Value™ indicates the stock is 19.8% overvalued at $211.41. Despite a strong GF Score™...
Bullish
This "Deal Dispatch" article covers major corporate acquisitions and strategic evaluations. Key announcements include Penske Media Corp.'s purchase of...
Bullish
Healthcare stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV), achieved new 52-week highs, indicating strong performance wi...
Neutral
AbbVie's growth trajectory, following its reliance on Humira, is now primarily driven by Skyrizi and Rinvoq. While Skyrizi shows strong growth, a rece...
Neutral
This article compares AbbVie and Pfizer as investment options for 2026, focusing on their post-pandemic growth strategies, drug pipelines, and financi...
Neutral
AbbVie's acquisition of Apogee Therapeutics for nearly $11 billion, though costly and not accretive until 2032, is seen by William Blair as having lon...
Neutral
AbbVie announced its agreement to acquire Apogee Therapeutics for approximately $10.9 billion. This acquisition is not a new strategic direction for A...
Bullish
AbbVie (ABBV) is reportedly close to a $10.9 billion deal to acquire anti-inflammatory drug developer Apogee Therapeutics (APGE). This acquisition wou...
Neutral
Monetary Solutions Ltd purchased a new position in AbbVie Inc. (NYSE:ABBV – Free Report) in the 4th quarter, according to the company in its most rece...
AbbVie Inc. is reportedly nearing an $11 billion all-cash deal to acquire Apogee Therapeutics Inc. This acquisition would strengthen AbbVie's anti-inf...
Bullish
AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to stockholders of record as of July 15, 2026. Sinc...
Neutral
Investment Management Corp of Ontario boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.3% in the 4th quarter, HoldingsChannel...